Mediso's Breakthrough in MRI Technology: Successful Tech Transfer from SSI Signals New Era

Mediso Revolutionizes MRI Technology with SSI Tech Transfer

Mediso, a prominent player in medical imaging technology, has made a significant leap forward in MRI system development by successfully completing the first phase of technology transfer from Superconducting Systems Inc. (SSI), a subsidiary of IMRIS. This agreement, finalized on May 9, 2025, establishes a strong foundation for Mediso's ambition to gain full control over its MRI manufacturing capabilities and to innovate within this crucial medical field.

Over the past decade, Mediso has effectively utilized SSI's advanced cryogen-free superconducting magnets in their MRI systems. This partnership has resulted in the development of the widely recognized nanoScan® 3T and 7T MRI systems, which have been instrumental in preclinical MRI applications. One of the hallmark features of these pioneering systems is their ability to operate without the use of liquid helium or other cryogens, which not only reduces operational costs but also makes the systems environmentally friendly.

The completion of the initial phase of this technology transfer signifies a pivotal moment for Mediso as it gears up to enhance its magnet manufacturing capabilities in Europe. The company anticipates that full-scale production will commence by the end of the year, bringing with it enhanced quality management processes that Mediso is known for.

Gergo Bagamery, the Director of Preclinical Product Development at Mediso, emphasized the importance of this achievement in their vertical integration strategy. "This is the last piece of the puzzle for Mediso for a complete vertical integration of its MRI products and the way forward in developing new MRI systems, up to 9.4T," he stated. With the ownership of this magnet technology, Mediso is now positioned to innovate with new designs adaptable to various field strengths and bore sizes, providing unmatched flexibility to meet diverse imaging needs.

The technology transfer has also granted Mediso access to SSI's core intellectual property and patented innovations in the realm of preclinical MRI. This is expected to facilitate the development of new conduction-cooled superconducting magnets that can achieve bore sizes optimized for magnetic field strengths up to 9.4T. Such advancements are anticipated to advance the capabilities and efficiency of MRI systems, redefining standards in both research and clinical settings.

Shahin Pourrahimi, CTO of SSI, praised the long-term collaboration with Mediso, reflecting on their shared progress in cryogen-free magnet technology for imaging purposes. He expressed excitement for the potential developments this technology transfer could unlock, stating that the progression of this technology would benefit the imaging field broadly.

Marc Buntaine, CEO of IMRIS, also lent his confidence to this process, asserting that Mediso's robust manufacturing capabilities combined with its commitment to innovation would enable the technology's global reach and impact.

As Mediso continues on this path, its overarching mission remains to deliver cutting-edge, compact, and fully integrated imaging solutions that cater to both research applications and clinical environments. This strategic move not only fortifies Mediso’s position in the medical imaging space but also serves as a testament to its dedication to advancing MR imaging technology for better patient outcomes.